IanFVA BRAND OF IONAFAIan Financial VisionAI-Driven. Independent. For Everyone.

Healthcare Valuations

Latest fair-value assessments and target prices by sector.

$90.81

RDNT Valuation Report 2026-08-11

RadNet, Inc. operates a network of diagnostic imaging centers, driving revenue through fee-for-service procedures with a focus on advanced modalities. Recent performance shows record quarterly revenue and EBITDA, fueled by increased imaging volumes and a shift towards higher-margin services – now 29.9% of volumes. The Digital Health segment contributes to revenue diversification with $105.5M ARR, though EBITDA contribution remains modest due to ongoing investment. The company maintains a conservative balance sheet with $726.3M cash and 1.8x net debt to EBITDA, enabling continued acquisitions and AI integration, highlighted by FDA clearance of its DeepHealth ultrasound solution. Upwardly revised 2026 guidance reflects management confidence. Strategic initiatives emphasize advanced imaging and digital health, supported by a robust financial position, but success depends on favorable reimbursement rates, cost management, and scaling the Digital Health segment. While macroeconomic factors present challenges like inflation and potential unemployment increases, RadNet’s focus on high-margin services and technological advancements positions it for sustained growth, contingent on strategic acquisitions and operational efficiency. Recent shifts demonstrate a more aggressive growth strategy with increased M&A activity and a focus on AI-driven solutions.

$120.49

BBIO Valuation Report 2026-08-11

BridgeBio Pharma develops and commercializes genetically-driven therapies for rare diseases, currently generating revenue primarily from Attruby, a treatment for transthyretin amyloid cardiomyopathy. While revenue increased significantly (311% year-over-year), recent financial results show continued net losses due to substantial R&D investment. A recent $1 billion equity raise mitigates near-term liquidity risk and funds pipeline expansion, encompassing 30 development programs including late-stage candidates for achondroplasia, congenital adrenal hyperplasia, and a near-term FDA decision on encaleret for Autosomal Dominant Hypocalcemia Type 1. Investor sentiment is mixed, with institutional activity showing both increased and decreased positions. The company’s valuation is heavily dependent on successful pipeline execution and market penetration of new therapies. Strategic shifts over the past four quarters demonstrate a move towards streamlined operations, disciplined capital allocation, and a focus on commercialization. Key risks include regulatory scrutiny, supply chain vulnerabilities, and competitive pressures, alongside a complex capital structure. Ultimately, BridgeBio’s success hinges on navigating macroeconomic conditions, advancing its pipeline through approvals, and achieving sustainable profitability.

$343.91

AXSM Valuation Report 2026-08-11

Axsome Therapeutics is a clinical-stage biopharmaceutical company with revenue currently driven by Auvelity, Sunosi, and Symbravo, reaching $218.4 million in Q2 2026—a 46% year-over-year increase largely from Auvelity sales. Despite revenue growth, the company continues to report net losses, with Q2 2026 losses at $0.99 per share, indicating high investment in sales and marketing. Its commercial strategy focuses on Auvelity, with a peak sales projection of $8 billion, and a developing pipeline including AXS-07 and AXS-12 (NDA accepted, PDUFA date May 1, 2027) and AXS-05. Institutional activity is mixed, with some investment and insider selling. The firm’s valuation relies heavily on pipeline success and Auvelity’s continued growth. Macroeconomic factors present both opportunities—modest GDP growth—and challenges—rising unemployment and inflation. Axsome has shifted towards aggressive capital allocation, funding growth through debt, equity, and acquisitions, but faces challenges achieving profitability and positive cash flow. Recent balance sheet changes demonstrate a dynamic approach to leverage and strategic investments, though working capital intensity remains elevated, requiring continued access to capital.

$35.29

HIMS Valuation Report 2026-08-11

Hims & Hers Health, Inc. is a vertically integrated telehealth platform delivering personalized health and wellness solutions via subscription access to medical professionals and products. While demonstrating substantial revenue growth (nearly 40% YoY, projected $3.1-3.3B annual revenue) and a subscriber base approaching 3 million, the company currently faces profitability challenges driven by investments in branded GLP-1 weight-loss treatments and international expansion. This expansion is impacting margins despite subscriber growth. Strategic emphasis on GLP-1s fuels revenue but compresses margins, necessitating careful ROI evaluation. The company’s financial health is complicated by working capital intensity and recent legal inquiries regarding fiduciary duty and securities law. Effective inventory management and achieving scale are critical. Macroeconomic factors present both opportunities (slight GDP increase) and challenges (rising unemployment, inflation). Maintaining competitive pricing amidst inflation and navigating stable but potentially restrictive interest rates are key. Recent acquisitions demonstrate an aggressive capital allocation strategy focused on growth and operational efficiency, with executive compensation tied to performance. While the company shows potential for future margin expansion, sustained profitability remains uncertain and dependent on cost management, strategic investment returns, and navigating a complex regulatory and economic landscape.

$87.73

RPRX Valuation Report 2026-08-11

Royalty Pharma (RPRX) operates a unique healthcare business model acquiring royalty streams from biopharmaceutical products, generating revenue from a percentage of net sales without direct drug development costs. Recent financial performance shows portfolio receipts increased 6% year-over-year to $773 million in Q2 2026, prompting raised full-year guidance of $3.4-3.5 billion. Strategic initiatives include sourcing royalty opportunities from academic institutions and a $425 million acquisition expanding its oncology portfolio. The company maintains a stable, high-margin revenue stream, bolstered by a low-intensity asset base and a consistent dividend. Macroeconomic conditions, including moderate GDP growth and stable inflation, support continued healthcare investment. RPRX’s financial structure benefits from stable interest rates and disciplined capital allocation. While institutional activity fluctuates, the overall outlook is positive. The firm’s recent strategic shifts—internalizing management, focusing on long-term growth, and optimizing its portfolio—position it for sustained earnings power, despite cyclical volatility in revenue and cash flow. Valuation metrics suggest a moderate dispersion with a projected near-term price increase to $69.32, and a longer-term target of $87.73, reflecting confidence in future growth.

$695.74

COR Valuation Report 2026-08-11

Cencora, Inc. is a pharmaceutical wholesaler focused on efficient distribution of branded, generic, and specialty drugs to hospitals, pharmacies, and providers. The company is strategically shifting towards higher-margin, service-oriented revenue – including pharmacy management, data analytics, and clinical trial support – while managing substantial inventory. Recent performance shows 5.1% revenue growth to $84.8 billion in Q3 2026, exceeding estimates, driven by specialty pharmaceuticals. Management increased its full-year earnings outlook despite headwinds from GLP-1 receptor agonists impacting volume. A key strategic move is the proposed $3.5 billion acquisition of veterinary product provider Covetrus, currently under FTC review. Institutional investors are accumulating shares, indicating confidence, though stock performance remains sensitive to market conditions. Cencora is prioritizing specialty pharmaceuticals, leveraging its distribution network and data analytics to counter generic drug pricing pressures. Macroeconomic factors, including modest GDP growth and potential unemployment increases, are being monitored. Inflationary pressures impact costs, while the Covetrus acquisition introduces both diversification and regulatory risk. Over the past year, Cencora has aggressively pursued acquisitions, restructured its portfolio, and focused on operational efficiency, demonstrating a commitment to shareholder returns through share repurchases. The company navigates a dynamic sector with consistent cash flow and a fair valuation relative to its growth profile.

$7.03

CLOV Valuation Report 2026-08-10

Clover Health Investments is transitioning from a direct Medicare Advantage provider to a technology-enabled services company, focusing on its Clover Assistant platform for external licensing. Recent financial performance shows improving revenue ($743M, +56% YoY) and profitability (net income of $28M, adjusted EBITDA of $41M, +139%), driven by 48% membership growth to 157,309. Full-year 2026 guidance is positive, projecting revenue of $2.92-3.00B. However, a recent cybersecurity incident poses operational and reputational risks. Valuation hinges on sustained membership growth and margin improvement, with a focus on implied EBITDA multiples. The company faces macroeconomic headwinds including potential impacts from unemployment, inflation, and interest rates, but aims to mitigate these through technology and efficiency. Strategic shifts include exiting the ACO REACH program and prioritizing Counterpart Health. While demonstrating improved financial metrics, Clover’s performance remains volatile, with cyclical revenue and profitability requiring continued scrutiny of cost structures and capital allocation.

$104.12

ZTS Valuation Report 2026-08-08

Zoetis Inc. is the global leader in animal health, generating revenue through veterinary pharmaceuticals, vaccines, diagnostics, and related services for both production and companion animals. While recent Q2 2026 earnings per share marginally exceeded expectations, overall revenue fell short, prompting a downward revision of full-year guidance due to softening demand in the companion animal segment – driven by reduced vet visits, price sensitivity, and increased competition. This has led to a valuation discount reflecting these concerns, despite robust R&D investment and a strong market position. The company is responding with promotional activity to defend market share, potentially impacting gross margins. Macroeconomic factors, including stable but elevated inflation and borrowing costs, continue to pressure discretionary spending on pet healthcare. Zoetis is focusing on operational efficiencies under new leadership while facing potential legal liabilities from ongoing securities class action lawsuits. Long-term growth relies on increasing pet ownership and global protein demand, but requires navigating current challenges and restoring revenue momentum. Recent strategic shifts prioritize innovation, cost control, and a diversified product portfolio to mitigate risks and drive future profitability.

$485.88

NTRA Valuation Report 2026-08-07

Natera is a molecular diagnostics company experiencing robust revenue growth (38% YOY to $753M in Q2 2026) driven by tests like Panorama and Signatera, alongside expanding offerings in reproductive health, oncology, and organ transplant monitoring. Despite current net losses ($0.47/share in Q2 2026), high gross margins (64.5%) and strategic initiatives – including Signatera’s submission for approval in Japan and EU certification – suggest a path to profitability. Investor activity is mixed, with institutional accumulation balanced by some profit-taking. The company is focused on geographic expansion and product pipeline advancement, supported by strong investor conviction (e.g., Stanley Druckenmiller holds 18% of assets in NTRA). Macroeconomic stability supports healthcare spending, while moderate inflation presents cost pressures. Recent strategic shifts prioritize R&D investment, acquisitions (Foresight Diagnostics), and scaling operations, moving from cost management to aggressive growth. Financial performance shows improving but volatile profitability and cash flow, requiring disciplined capital allocation. Valuation metrics indicate moderate dispersion and potential for appreciation, with a long-term target price around $485.9, though potential plateaus exist.

$205.01

INSM Valuation Report 2026-08-07

Insmed Incorporated focuses on rare disease biopharmaceuticals, transitioning from reliance on ARIKAYCE to increasing revenue diversification led by BRINSUPRI. Q2 2026 revenues reached $425.5 million, driven by $309.2 million in BRINSUPRI sales (a 49% sequential increase), while ARIKAYCE grew modestly at 8%. Net loss narrowed to $0.52 per share, indicating progress towards profitability. Management raised full-year BRINSUPRI revenue guidance to $1.25-$1.4 billion, with a long-term peak exceeding $7 billion, and projects combined peak revenues of over $14 billion across its pipeline including TPIP for pulmonary arterial hypertension. The company is strategically investing in R&D (currently 17%, aiming for 20%) and acquisitions to drive “second curve” growth. Financial performance shows improving cash flow despite persistent net losses, with a focus on operational efficiency and working capital management. Institutional investor activity is mixed. Macroeconomic stability supports demand for therapies like BRINSUPRI, though inflation and interest rates require careful monitoring. Insmed’s valuation suggests moderate appreciation potential, with target prices ranging from $138.65 (next quarter) to over $205 in the long term, contingent on successful execution of its growth strategy and pipeline development.